Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Is PSA doubling time reliable as a progression risk criterion for patients with low-risk prostate cancer in an active surveillance programme?

Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  1. Enzalutamide monotherapy in patients with hormone-naïve prostate cancer: 1.year extended follow-up of a phase 2 study.

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  2. ERG-expression is an independent predictor of disease progression during active surveillance

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskning

  3. Baseline PSA level in prediction of prostate cancer risk and aggressiveness: A Danish population-based cohort study.

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

  4. Efficacy and safety of enzalutamide monotherapy in hormone-naive prostate cancer.

    Publikation: Bidrag til tidsskriftKonferenceabstrakt i tidsskriftForskningpeer review

Vis graf over relationer
OriginalsprogEngelsk
TidsskriftEuropean Urology Supplements
Vol/bind12
Udgave nummer1
Sider (fra-til)e273-e274
Antal sider1
ISSN1569-9056
StatusUdgivet - 2013
Begivenhed28th Annual Congress, European Association of Urology - Milan, Italien
Varighed: 15 mar. 201319 mar. 2013
Konferencens nummer: 28

Konference

Konference28th Annual Congress, European Association of Urology
Nummer28
LandItalien
ByMilan
Periode15/03/201319/03/2013

Begivenhed

28th Annual Congress, European Association of Urology

15/03/201319/03/2013

Milan, Italien

Begivenhed: Konference

ID: 38593377